3-(-Imidazol-2-Yl)-2,3,8,8a-Tetrahydroindolizin-5()-One Derivatives are Useful as Factor Xia Inhibitors and Their Preparation.
作者信息
Al-Horani Rami A
机构信息
Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans LA 70125 United, States.
出版信息
Cardiovasc Hematol Agents Med Chem. 2023;21(3):240-242. doi: 10.2174/1871525721666230118140531.
Abstract
摘要
相似文献
1
3-(-Imidazol-2-Yl)-2,3,8,8a-Tetrahydroindolizin-5()-One Derivatives are Useful as Factor Xia Inhibitors and Their Preparation.3-（-咪唑-2-基）-2,3,8,8a-四氢中氮茚-5（）-酮衍生物作为凝血因子Ⅹa抑制剂是有用的及其制备方法。 （注：原文中5后面括号内容不完整，翻译时保留原样）
Cardiovasc Hematol Agents Med Chem. 2023;21(3):240-242. doi: 10.2174/1871525721666230118140531.
2
Synthesis, Docking, and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo[3,2,1-]Quinolin-2(1)-one as New Inhibitors of Factor Xa and Factor XIa.吡咯并[3,2,1-]喹啉-2(1H)-酮类杂合衍生物的合成、对接及体外抗凝血活性研究作为新型因子 Xa 和因子 XIa 抑制剂。
Molecules. 2020 Apr 19;25(8):1889. doi: 10.3390/molecules25081889.
3
Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors.哒嗪和哒嗪酮衍生物作为强效且选择性的凝血因子XIa抑制剂。
Bioorg Med Chem Lett. 2018 Apr 1;28(6):987-992. doi: 10.1016/j.bmcl.2018.02.049. Epub 2018 Feb 27.
4
Fragment-Based Lead Generation of 5-Phenyl-1-pyrazole-3-carboxamide Derivatives as Leads for Potent Factor Xia Inhibitors.基于片段的 5-苯基-1-吡唑-3-甲酰胺衍生物的先导化合物生成，作为强效因子 Xia 抑制剂的先导化合物。
Molecules. 2018 Aug 10;23(8):2002. doi: 10.3390/molecules23082002.
5
Enantiospecific synthesis and cytotoxicity of 7-(4-methoxyphenyl)-6-phenyl-2,3,8,8a-tetrahydroindolizin-5(1H)-one enantiomers.7-(4-甲氧基苯基)-6-苯基-2,3,8,8a-四氢中氮茚-5(1H)-酮对映体的对映选择性合成及其细胞毒性
Bioorg Med Chem. 2008 Apr 15;16(8):4367-77. doi: 10.1016/j.bmc.2008.02.073. Epub 2008 Mar 4.
6
Synthesis, in vitro and in vivo cytotoxicity of 6,7-diaryl-2,3,8,8a-tetrahydroindolizin-5(1H)-ones.6,7-二芳基-2,3,8,8a-四氢中氮茚-5(1H)-酮的合成、体外和体内细胞毒性
Bioorg Med Chem Lett. 2007 Aug 15;17(16):4703-7. doi: 10.1016/j.bmcl.2007.05.103. Epub 2007 Jun 13.
7
Cardiotonic agents. 3. Synthesis and biological activity of novel 6-(substituted 1H-imidazol-4(5)-yl)-3(2H)-pyridazinones.强心剂。3. 新型6-（取代的1H-咪唑-4（5）-基）-3（2H）-哒嗪酮的合成及生物活性
J Med Chem. 1986 Feb;29(2):261-7. doi: 10.1021/jm00152a015.
8
Design, synthesis and biological evaluation of novel FXIa inhibitors with 2-phenyl-1H-imidazole-5-carboxamide moiety as P1 fragment.设计、合成及新型 FXIa 抑制剂的生物评价，以 2-苯基-1H-咪唑-5-甲酰胺为 P1 片段。
Eur J Med Chem. 2021 Aug 5;220:113437. doi: 10.1016/j.ejmech.2021.113437. Epub 2021 Apr 20.
9
Synthesis, biological screening and in silico studies of new N-phenyl-4-(1,3-diaryl-1H-pyrazol-4-yl)thiazol-2-amine derivatives as potential antifungal and antitubercular agents.合成、生物筛选及新型 N-苯基-4-(1,3-二芳基-1H-吡唑-4-基)噻唑-2-胺衍生物的计算机辅助研究作为潜在的抗真菌和抗结核药物。
Eur J Med Chem. 2023 Oct 5;258:115548. doi: 10.1016/j.ejmech.2023.115548. Epub 2023 Jun 7.
10
Preparation and characterization of S-[2-carboxy-1-(1H-imidazol-4-yl)ethyl]glutathione and its derivatives as proposed precursors of S-[2-carboxy-1-(1H-imidazol-4-yl)ethyl]cysteine, a compound found in human urine.S-[2-羧基-1-(1H-咪唑-4-基)乙基]谷胱甘肽及其衍生物作为人尿中发现的化合物S-[2-羧基-1-(1H-咪唑-4-基)乙基]半胱氨酸的潜在前体的制备与表征
Biochim Biophys Acta. 1993 Jun 11;1157(2):192-8. doi: 10.1016/0304-4165(93)90064-f.
本文引用的文献
1
Factor IX(a) inhibitors: an updated patent review (2003-present).因子 IX(a)抑制剂：更新的专利审查（2003 年至今）。
Expert Opin Ther Pat. 2022 Apr;32(4):381-400. doi: 10.1080/13543776.2022.2026926. Epub 2022 Jan 17.
2
Emerging agents for the treatment and prevention of stroke: progress in clinical trials.新兴的卒中治疗和预防药物：临床试验进展。
Expert Opin Investig Drugs. 2021 Oct;30(10):1025-1035. doi: 10.1080/13543784.2021.1985463. Epub 2021 Oct 13.
3
Factor XI Inhibition to Uncouple Thrombosis From Hemostasis: JACC Review Topic of the Week.因子 XI 抑制：将血栓形成与止血分离——JACC 本周综述专题。
J Am Coll Cardiol. 2021 Aug 10;78(6):625-631. doi: 10.1016/j.jacc.2021.06.010.
4
The rebirth of the contact pathway: a new therapeutic target.接触途径的重生：一个新的治疗靶点。
Curr Opin Hematol. 2020 Sep;27(5):311-319. doi: 10.1097/MOH.0000000000000603.
5
Role of Factor XIa and Plasma Kallikrein in Arterial and Venous Thrombosis.因子 XIa 和血浆激肽释放酶在动脉和静脉血栓形成中的作用。
Thromb Haemost. 2020 Jun;120(6):883-993. doi: 10.1055/s-0040-1710013. Epub 2020 May 6.
6
Targeting factor XI(a) for anticoagulation therapy: a patent landscape.以凝血因子XI（a）为靶点的抗凝治疗：专利态势
Pharm Pat Anal. 2020 Jan;9(1):3-5. doi: 10.4155/ppa-2020-0002. Epub 2020 Feb 14.
7
Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present).因子 XI(a)抑制剂治疗血栓：更新的专利审查（2016 年至今）。
Expert Opin Ther Pat. 2020 Jan;30(1):39-55. doi: 10.1080/13543776.2020.1705783. Epub 2019 Dec 19.
8
Factor XIa Inhibitors as New Anticoagulants.XIa 因子抑制剂：新型抗凝药物。
J Med Chem. 2018 Sep 13;61(17):7425-7447. doi: 10.1021/acs.jmedchem.8b00173. Epub 2018 May 18.
9
Recent advances in the discovery and development of factor XI/XIa inhibitors.近年来，因子 XI/XIa 抑制剂的发现和开发取得了新进展。
Med Res Rev. 2018 Sep;38(6):1974-2023. doi: 10.1002/med.21503. Epub 2018 May 4.
10
Inhibition of Factors XI and XII for Prevention of Thrombosis Induced by Artificial Surfaces.抑制因子 XI 和 XII 预防人工表面诱导的血栓形成。
Semin Thromb Hemost. 2018 Feb;44(1):60-69. doi: 10.1055/s-0037-1603937. Epub 2017 Sep 12.
Zotero 插件